Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT) against certain of their officers and directors for alleged breaches of fiduciary duty.

If you purchased Corcept shares before October 31, 2024, and have continuously held those shares, you may have standing to seek corporate governance reforms at Corcept, including improvements to regulatory-risk oversight, clinical-data disclosures, internal controls, and executive accountability.

Complaint Allegations
A previously filed securities class action complaint alleges that Corcept and certain executives misled investors about the likelihood of FDA approval of relacorilant for patients with hypercortisolism. Defendants allegedly expressed confidence in the application while failing to disclose repeated FDA concerns about whether the supporting clinical evidence was adequate. On December 31, 2025, Corcept announced that the FDA had issued a Complete Response Letter requiring additional evidence of effectiveness before it could reach a favorable benefit-risk assessment. The complaint alleges that this disclosure revealed previously undisclosed regulatory risks.